CN114432329A - Application of geniposide in preparation of medicine for treating psoriasis - Google Patents
Application of geniposide in preparation of medicine for treating psoriasis Download PDFInfo
- Publication number
- CN114432329A CN114432329A CN202210175449.6A CN202210175449A CN114432329A CN 114432329 A CN114432329 A CN 114432329A CN 202210175449 A CN202210175449 A CN 202210175449A CN 114432329 A CN114432329 A CN 114432329A
- Authority
- CN
- China
- Prior art keywords
- geniposide
- psoriasis
- group
- skin
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 title claims abstract description 64
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 title claims abstract description 59
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 title claims abstract description 59
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims description 22
- 239000003826 tablet Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 32
- 210000000952 spleen Anatomy 0.000 abstract description 24
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract description 23
- 241001465754 Metazoa Species 0.000 abstract description 23
- 229960002751 imiquimod Drugs 0.000 abstract description 21
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 abstract description 21
- 206010015150 Erythema Diseases 0.000 abstract description 17
- 231100000321 erythema Toxicity 0.000 abstract description 17
- 229960000485 methotrexate Drugs 0.000 abstract description 14
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 13
- 206010040882 skin lesion Diseases 0.000 abstract description 13
- 231100000444 skin lesion Toxicity 0.000 abstract description 13
- 230000037396 body weight Effects 0.000 abstract description 10
- 230000008719 thickening Effects 0.000 abstract description 10
- 239000013641 positive control Substances 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000003022 colostrum Anatomy 0.000 description 4
- 235000021277 colostrum Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- -1 iridoid glycoside compound Chemical class 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 241000207925 Leonurus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940030999 antipsoriatics Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930182489 iridoid glycoside Natural products 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000013309 psoriasis mouse model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- CUJMCPPBTUATEJ-UHFFFAOYSA-N 1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)ethanone Chemical compound C1=CC=C2[N+](=O)C(C(=O)C)=C(C)N([O-])C2=C1 CUJMCPPBTUATEJ-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- ZROGCCBNZBKLEL-FHXNIQKESA-N Astilbin Natural products O([C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZROGCCBNZBKLEL-FHXNIQKESA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZROGCCBNZBKLEL-MPRHSVQHSA-N astilbin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1 ZROGCCBNZBKLEL-MPRHSVQHSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000003563 glycoside group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of geniposide in preparing a medicine for treating psoriasis. The geniposide can effectively relieve erythema, scale and thickening of the skin at the skin lesion of the Babl/c mouse induced by imiquimod, the PASI score of the psoriasis mouse is obviously reduced, and the PASI score of a geniposide high-dose group is slightly superior to that of a positive control medicament. The basic morphology of the psoriasis mice is improved better than that of methotrexate tablets by moderate and high doses of geniposide, including the glossiness and the body weight of the hair of animals. The moderate and high doses of the geniposide can obviously reduce the abnormal rise of the psoriasis spleen index induced by imiquimod, have no obvious difference with a methotrexate tablet, and have better safety than the methotrexate.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of geniposide in preparation of a medicine for treating psoriasis.
Background
Psoriasis is a chronic recurrent autoimmune-related skin disease genetically determined by polygenic genes, induced by stimulation with multiple environmental factors, and has the appearance of erythema overlaid with thickened silvery-white scales. The appearance of psoriasis is not elegant, which causes patients to have a strong self-depreciation mood, and affects their employment and quality of life. Long-term treatment consumption not only places a severe economic and mental burden on the patient, but also causes a huge social burden with high morbidity and long-term treatment.
Modern medicine determines treatment strategies based on the severity of the psoriasis condition. Topical treatment is used primarily for mild patients, systemic treatment is used in combination with topical treatment for moderately severe patients, and biologic treatment is used for patients who have failed traditional treatment methods.
However, topical treatment is very easy to relapse, even rebound, and has large irritation, and has side effects of skin atrophy, hypercalcemia and the like. In recent years, with the development of biotechnology, biological therapy has become a major complement to traditional therapies for psoriasis. Biological therapy is generally more effective, however, biological agents can cause significant increases in the incidence of infectious diseases (such as tuberculosis, pneumonia, enteritis, sepsis, etc.) and tumors (such as non-melanoma skin cancer, lung cancer, breast cancer, colon cancer, stomach cancer, prostate cancer, etc.).
Disclosure of Invention
The invention aims to provide application of geniposide in preparing a medicine for treating psoriasis.
The purpose of the invention is realized by the following technical scheme:
the application of geniposide in preparing medicine for treating psoriasis;
the geniposide is iridoid glycoside compound, namely geniposide, dimethomorphin glucoside dehydrogeniposide, CAS accession number is 2452-63-8, and molecular formula is C17H24O10Molecular weight is 388.37, and the structure is shown as the following formula:
the imiquimod-induced Babl/c mouse psoriasis model is used as a drug screening model, and experimental results show that Geniposide (Geniposide) can effectively relieve erythema, scales and thickening of skin at an imiquimod-induced Babl/c mouse skin lesion, the PASI score of a psoriasis mouse is remarkably reduced, the PASI score of a Geniposide high-dose group is slightly superior to that of a positive control drug (methotrexate tablet), but no statistical difference exists. The basic morphology of the psoriasis mouse is improved better than that of the methotrexate tablet by moderate and high doses of geniposide, including the glossiness and the body weight of the hair of animals. The moderate and high doses of the geniposide can obviously reduce the abnormal rise of the spleen index of psoriasis induced by imiquimod, and have no obvious difference with methotrexate tablets.
Therefore, the geniposide can treat psoriasis and is used for preparing a medicament for treating psoriasis;
the medicine can also contain other active ingredients capable of treating psoriasis;
the medicine can also contain more than one pharmaceutically acceptable carrier; the carrier is preferably a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, an adsorption carrier, a surfactant or a lubricant, and the like.
The medicine can be an external preparation (skin administration preparation), an oral preparation or an injection;
the external preparation comprises emulsion, cream, spray and gel;
the oral dosage forms comprise tablets, capsules, granules and syrups.
The drug is suitable for oral delivery or transdermal delivery, and after administration, the symptoms of psoriasis vulgaris (erythema, thickening, scaling) are remarkably improved. The invention can be applied to patients needing treatment by percutaneous or oral routes, and the dosage is generally 0.001-10g/d, and can be determined by doctors according to specific conditions.
Compared with the prior art, the invention has the following advantages and effects:
the geniposide can effectively relieve psoriasis-like lesions of the Babl/c mice induced by imiquimod, improve pathological forms of skin lesions, scales, thickening and the like of the back skin of the Babl/c mice, has a PASI score which is obviously lower than that of a model group, has no obvious difference with a positive control drug (methotrexate tablets), and can be used for preparing a drug for treating psoriasis.
Drawings
FIG. 1 is a photograph of the skin of the back of an experimental mouse 6 days after administration.
FIG. 2 is a photograph of hair on the back of the neck of an experimental mouse 6 days after molding.
FIG. 3 is a graph showing the change in body weight of experimental mice.
FIG. 4 shows spleen size and spleen index of experimental mice after administration.
FIG. 5 is a photograph of the skin on the back of an experimental mouse after administration.
FIG. 6 is a graph of erythema, hypertrophy, scaling score and PASI total score for each group of experimental mice.
FIG. 7 is a graph showing the results of HE staining of skin on the back of mice.
Wherein the content of the first and second substances,##is compared with the normal group, P is less than 0.01;ΔΔis compared with the model group, P is less than 0.01;**compared with MTX group, P is less than 0.01,*is P < 0.05.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but the present invention is not limited thereto.
Example 1
Imquimod-induced psoriasis model drug effect experiment
Animals and groups: SPF-grade BALB/c mice 12, male, 8-week-old, were purchased from Guangdong province medical laboratory animal center and produced permit number SCXK (Guangdong) 2013-. The experimental animals are raised in a barrier environment animal house of traditional Chinese medicine institute in Guangdong province, the room temperature is 20-25 ℃, the relative humidity is 40-70%, and the light and shade alternate day and night within 12h/12 h. The experiment was approved by the ethical committee of the traditional Chinese medicine institute of Guangdong province (NO. 2021090). 12 BALB/c mice were randomly divided into a normal group, a model group, a geniposide group, a leonuroside A group, and a total of 4 groups, each group consisting of 3 mice, according to body weight.
Drugs and reagents: the experiment selects iridoid components of geniposide and leonurus glycoside A, the batch numbers of which are S14J10Y79596 and J11GB154353 respectively, which are purchased from Shanghai Yuanye Biotechnology Co., Ltd, and pure water is added respectively to prepare 2.00mg/mL and 2.00mg/mL during use, and the mixture is stored in a refrigerator at 4 ℃ for standby. Imiquimod cream, batch number: 19040540, Sichuan Mingxin pharmaceutical industry, Inc.
Medicine efficacyTesting: the animals were observed daily for baseline and weighed. Animals were shaved on their backs one day before molding to form a skin exposure area of approximately 2cm x 3 cm. Except for normal control group, each group of mice is coated with imiquimod cream 50mg in the back hairless area every morning and 10 mL/kg in the afternoon-1·d-1The volume is perfused to the stomach, the normal group and the model group are given pure water with the same volume for 6 days continuously, photographing is carried out every day, the severity of skin lesions (PASI) is graded, the erythema (erythema), the scales (scales) and the infiltration thickening degree (thickness) are respectively 0-4 (0, none; 1, mild; 2, moderate; 3, severe; 4, extreme severe), and the total grade is obtained by accumulating 3 grades. After 24h of the last dose, the animals were sacrificed under anesthesia, the skin and spleen were collected and the spleen was weighed.
The experimental results are as follows:
comparison of skin lesion extent, PASI score, spleen coefficient in psoriasis mice
The skin on the back of the mice after 6 days of administration is shown in fig. 1, the skin of the normal group animals has smooth appearance, ruddy appearance and no skin damage, deep red plaques appear in the skin area on the back of the mice after imiquimod intervention, partial scales are covered on the skin damage, and the PASI score is obviously increased (P is less than 0.01) (see table 1). Compared with the model group, the skin of the geniposide group psoriasis mouse has the advantages that the erythema color and area, scales, skin folds and bulges are effectively improved, and the PASI score is obviously reduced (P is less than 0.05); the leonuroside A group has no obvious relief on symptoms such as erythema, scale, thickening and the like of skin lesion areas of psoriasis mice (P is more than 0.05).
TABLE 1 comparison of spleen index and PASI score results for each dosing group
As compared with the normal group, the test results,**p is less than 0.01; in comparison with the set of models,#P＜0.05
as shown in Table 1, spleen of psoriasis mice induced by imiquimod is abnormally increased, and spleen index of model mice is obviously increased (P is less than 0.01) compared with that of normal mice; compared with the model group, the spleen index of the geniposide group mice is obviously reduced (P is less than 0.05), and the spleen index of the leonurus glycoside group A mice is slightly increased, but has no statistical significance.
And (4) conclusion: the results of the preliminary experiments indicate that the geniposide has potential anti-psoriasis effect, while the leonurus glycoside A which is the iridoid glycoside component has no anti-psoriasis effect.
Example 2
Drug effect experiment of geniposide for resisting psoriasis
Animals and groups: SPF-grade BALB/c mice 48, male, 8-week-old, were purchased from Guangdong province medical laboratory animal center and produced permit number SCXK (Guangdong) 2013-. The experimental animals are raised in a barrier environment animal house of traditional Chinese medicine institute in Guangdong province, the room temperature is 20-25 ℃, the relative humidity is 40-70%, and the light and shade alternate day and night within 12h/12 h. The experiment was approved by the ethical committee of the traditional Chinese medicine institute of Guangdong province (NO. 2021090). 48 BALB/c mice were randomly divided into a normal group, a model group, a geniposide low, medium and high dose group, a methotrexate group, and a total of 6 groups, each of which was 8, based on body weight.
Drugs and reagents: methotrexate tablets, 2.50mg each, shanghai friendship pharmaceutical factory, inc, product batch no: 036140908, when in use, the pure water is added to prepare 0.10 mg/mL; geniposide, batch number: S14J10Y79596, purchased from Shanghai-derived leaf Biotechnology Co., Ltd, was prepared into 1.00, 2.00, 4.00mg/mL by adding pure water when used, and was stored in a refrigerator at 4 ℃ for further use. Imiquimod cream, batch number: 19040540, Sichuan Mingxin pharmaceutical industry, Inc.
And (3) pharmacodynamic experiment: observing animal basic condition every day, weighing at 10 mL/kg-1·d-1The administration is performed by volume gavage, i.e. the administration dose of geniposide is low, medium and high dose groups is respectively (10, 20, 40mg/kg), the dose of methotrexate is 1mg/kg, and the normal group and the model group are administered with purified water with equal volume 1 time per day for 12 days continuously. Animals were shaved on their backs one day before molding to form a skin exposure area of approximately 2cm x 3 cm. Mice in each group except the normal control group were coated with imiquimod cream 50mg on the dorsum depilatory area every morning at 7d, continuously molded for 6d, photographed every day, scored for skin lesion severity (PASI), and erythema treated(erythrema), scales (scales) and infiltration thickening degree (thickness) are 0-4 (0, none; 1, mild; 2, moderate; 3, severe; 4, very severe), and the total score is obtained by accumulating the 3 scores. After 24h of the last dose, the animals were sacrificed under anesthesia, the skin and spleen were collected and the spleen was weighed. And fixing, embedding, slicing and HE staining the skin of the skin lesion part for pathological observation.
Results of the experiment
1. Comparison of basic conditions in mice
1.1 Hair State comparison
After administration, the hair on the neck and back of the mice is bright as shown in figure 2, while the hair of the normal group animals is very rough and dull after the imiquimod intervention, and the positive drug MTX treatment can slightly improve the phenomenon, but the effect is not obvious. After the low-dose treatment of geniposide, the phenomenon of rough hair of mice is slightly improved, and the hair of the mice is more glossy than that of a model group. The geniposide middle dose group greatly improves the phenomenon of mouse hair lusterless and rough caused by imiquimod. The hair of the geniposide high-dose group is smooth and glossy and is almost similar to that of the normal group of animals. It is seen that the effect of improving hair roughness and lackluster caused by the mequindox model is gradually increased as the geniposide dosage is increased.
1.2 mouse weight changes
As shown in fig. 3, the body weight of the normal group mice showed a tendency to gradually increase within 13 days. The body weight of the model group is obviously reduced on the 9 th day of the experiment (3 rd day of the modeling), and the body weight is obviously reduced compared with the body weight of the normal group (P is less than 0.05); the weight loss was more significant on days 11-13 of the experiment (P < 0.01).
The weight change trend of the geniposide low-dose group mice is quite similar to that of the model group animals, the weight of the group animals is obviously reduced on the 9 th day, but the weight is gradually recovered on the 11 th to 13 th days of the experiment.
The weight of the mice in the geniposide medium and high dose groups is slightly reduced at the 9 th day of the experiment, and then recovery is started, and compared with the model group, the weight of the mice in the geniposide medium and high dose groups is obviously increased at the 11-13 days of the experiment (P is less than 0.01).
In addition, imiquimod dry prognosis, mice in the MTX group continued to lose weight, which was 13.22% less on day 13 compared to the initial body weight.
1.3 Effect on spleen size and spleen index
As shown in figure 4 and table 2, imiquimod intervention caused splenomegaly and an increase in spleen index. In the experiment, the spleen index of the normal group of mice is (35.04 +/-0.69 mg/10g), the spleen index of the model group of animals is (118.21 +/-9.24 mg/10g), and the spleen index of the mice is increased by 3.37 times compared with that of the normal group after the imiquimod intervention.
The spleen index of the geniposide in the low-dose group (103.91 +/-11.65 mg/10g), the middle-dose group (94.93 +/-5.08 mg/10g), the high-dose group (73.59 +/-7.69 mg/10g) and the MTX (53.43 +/-7.51 mg/10g) shows a reduction trend after the geniposide intervenes in imiquimod mice, wherein the spleen index between the geniposide in the middle-dose group and the high-dose group and the model group shows significant difference (P < 0.01) through statistical analysis. Compared with MTX group, the spleen indexes of low, medium and high doses of geniposide are all obviously increased (P is less than 0.01 or 0.05).
TABLE 2 comparison of spleen index for each administration group
In comparison with the normal group,##p is less than 0.01; in comparison with the set of models,ΔΔp is less than 0.01; in comparison with the MTX group,**p < 0.01 or*P＜0.05
2. Comparison of the Effect of skin lesion extent in psoriasis mouse model
As shown in fig. 5, the skin of the normal group of animals appeared smooth, ruddy, and no skin lesions, and dark red or purplish red patches and skin ridges appeared on the skin areas of the backs of the mice after imiquimod intervention, and the skin lesions were covered with hypertrophic scales. After the geniposide low-dose group is administrated for treatment, the erythema on the skin of the animal is reduced, but the scale and skin uplift symptoms of the animal are lighter than those of the animals in the model group; the middle and high dose animals with geniposide have obvious conditions of erythema color and area, scale, skin fold and bulge improvement; the MTX group significantly reduced thickening, scaling and erythema of the skin.
3. Effect on PASI score
The PASI scoring results are shown in a figure 6 and a table 3, three typical psoriasis symptoms of erythema, scales and infiltration appear at the skin lesion of the mice induced by imiquimod, and compared with a normal group, the PASI total score, the erythema, the hypertrophy and the scales of the model group are gradually increased and have statistical significance (P is less than 0.01). The erythema and thickening scores of the geniposide medium and high dose groups are obviously lower than those of the model group, and the PASI total score and the scale score of the geniposide low, medium and high dose groups are all obviously lower than those of the model group (P is less than 0.01). Compared with the methotrexate group, the total PASI score and the erythema, hypertrophy and scale score of the geniposide high-dose group have no obvious difference, which indicates that the medicinal effects of the geniposide and the methotrexate are equivalent.
TABLE 3 comparison of spleen index for each administration group
In comparison with the normal group,##p is less than 0.01; in comparison with the set of models,ΔΔp is less than 0.01; in comparison with the MTX group,**p < 0.01 or*P＜0.05
4. Effect of jasminoidin on skin pathological morphology of psoriasis mouse model
The pathological changes after HE staining are further analyzed in the experiment, as shown in fig. 7, compared with the control group, the pathological sections of the mouse skin lesion intervened by imiquimod can observe obvious thickening of the horny layer and the spinous layer and phenomena of hyperkeratosis or parakeratosis, and pathological changes such as Munro microcolonies, granular layer reduction, dermal inflammatory cell infiltration and capillary vessel hyperplasia. The low, medium and high dose groups of geniposide and MTX intervention all improved the above pathological changes to varying degrees.
The conclusion is that the geniposide has good psoriasis resistance, the effect of the geniposide is equivalent to that of the methotrexate serving as the first-line medicament at present, but the safety of the geniposide is superior to that of the methotrexate.
Example 3
A tablet for treating psoriasis
Prescription:
the preparation method comprises the following steps: weighing the geniposide raw material medicine, lactose and 75% of hydroxymethyl starch sodium according to the prescription amount, mixing, sieving with a 120-mesh sieve for 3 times, and mixing uniformly. Adding appropriate amount of binder to obtain soft material, sieving with 18 mesh sieve, drying wet granules in oven at 50 deg.C for 1 hr, grading with 18 mesh sieve, adding magnesium stearate and sodium hydroxymethyl starch (25% of prescription amount), mixing, and tabletting.
Example 4
A capsule for treating psoriasis
Prescription:
jasminoidin 100g
Starch 50g
Dextrin 50g
The preparation method comprises the following steps: weighing the geniposide raw material medicine, adding starch and dextrin, mixing well, performing wet granulation by using 90% ethanol as a wetting agent, performing vacuum drying at 50 ℃, performing granulation, sieving by a 40-mesh sieve and a 200-mesh sieve to remove fine powder, and filling the medicinal powder granules into No. 3 capsules under the environment that the humidity is lower than 60% to obtain the geniposide preparation.
Example 5
A granule for the treatment of psoriasis
Prescription
The preparation method comprises the following steps: dissolving beta-cyclodextrin in water, heating and stirring to dissolve the beta-cyclodextrin; dissolving geniposide in absolute ethyl alcohol, slowly dropping the geniposide into a beta-cyclodextrin water solution, and stirring; cooling, filtering to obtain crystal, washing, drying, pulverizing, and sieving with 40 mesh sieve.
Example 6
A syrup for treating psoriasis
Prescription:
the preparation method comprises the following steps: weighing geniposide, adding into propylene glycol, stirring and ultrasonically treating until the geniposide is dissolved, adding glycerol, and stirring uniformly; weighing sucrose, adding purified water (about 4/5), boiling, cooling, adding sodium benzoate, stirring for 15min, controlling pH at 3.0, adding dissolved astilbin solution under continuous stirring, stirring for 45min, filtering, cooling to room temperature, adding essence purified water to desired volume, and stirring.
Example 7
A microemulsion for treating psoriasis
Prescription:
the preparation method comprises the following steps: according to the formula, the preparation method comprises the steps of weighing polyethylene glycol glyceryl oleate (Labrafil M1944 Cs), polyoxyethylene hydrogenated castor oil EL35 and diethylene glycol monoethyl ether (Transcutol HP), stirring and mixing uniformly, adding geniposide into distilled water, stirring until the medicine is completely dissolved, adding into an oil phase, continuing stirring at a constant speed to obtain colostrum, and carrying out ultrasonic treatment on the colostrum until a light yellow transparent O/W type traditional Chinese medicine component combined microemulsion is formed.
Example 8
Emulsion for treating psoriasis
Prescription:
the preparation method comprises the following steps: according to the formula, the preparation method comprises the steps of weighing polyethylene glycol glyceryl oleate (Labrafil M1944 Cs), polyoxyethylene 40 hydrogenated castor oil (RH40) and diethylene glycol monoethyl ether (Transcutol HP), stirring uniformly, adding geniposide into distilled water, stirring until the medicines are completely dissolved, adding into an oil phase, continuing stirring at a constant speed to obtain colostrum, and carrying out ultrasonic treatment on the colostrum to obtain an opaque emulsion.
Example 9
A cream for the treatment of psoriasis
Prescription:
the preparation method comprises the following steps: weighing oil phase, octadecanol, white vaseline, glyceryl monostearate, water phase, tween 80, glycerol, ethylparaben and distilled water according to the above formula, respectively heating the oil phase and the water phase in a water bath kettle at 80 ℃, slowly pouring the water phase into the oil phase while stirring and uniformly dissolving, finally adding the geniposide raw material medicine, and continuously stirring until cooling to obtain the gardenoside.
Example 10
Spray for treating psoriasis
Prescription:
the preparation method comprises the following steps: weighing geniposide and ethanol according to the above formula, dissolving completely, sequentially adding azone, tween-80, glycerol, sodium benzoate and water, stirring well, filtering, and canning.
Example 11
Gel for treating psoriasis
Prescription:
the preparation method comprises the following steps: weighing carbomer 940, glycerol, absolute ethyl alcohol and distilled water, stirring uniformly, standing overnight, adding geniposide, stirring uniformly, sequentially adding azone and tween-80, adding distilled water to 100g, regulating pH to 5 with triethanolamine, adding 0.1g ethylparaben, stirring fully, and mixing uniformly to obtain the final product.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (7)
1. Application of geniposide in preparing medicine for treating psoriasis is provided.
2. Use according to claim 1, characterized in that: the medicine also contains other active ingredients capable of treating psoriasis.
3. Use according to claim 1, characterized in that: the medicine also contains more than one pharmaceutically acceptable carrier.
4. Use according to claim 3, characterized in that: the carrier is a sustained release agent, an excipient, a filler, an adhesive, a wetting agent, a disintegrating agent, an absorption enhancer, an adsorption carrier, a surfactant or a lubricant.
5. Use according to claim 1, characterized in that: the medicine is an external preparation, an oral preparation or an injection.
6. Use according to claim 5, characterized in that: the external preparation comprises emulsion, cream, spray and gel.
7. Use according to claim 5, characterized in that: the oral dosage forms comprise tablets, capsules, granules and syrups.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210175449.6A CN114432329A (en) | 2022-02-24 | 2022-02-24 | Application of geniposide in preparation of medicine for treating psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210175449.6A CN114432329A (en) | 2022-02-24 | 2022-02-24 | Application of geniposide in preparation of medicine for treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114432329A true CN114432329A (en) | 2022-05-06 |
Family
ID=81374083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210175449.6A Pending CN114432329A (en) | 2022-02-24 | 2022-02-24 | Application of geniposide in preparation of medicine for treating psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114432329A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115192589A (en) * | 2022-07-13 | 2022-10-18 | 滴可安(杭州)生物技术有限公司 | Application of neoisoliquiritin in preparation of psoriasis treatment medicine |
-
2022
- 2022-02-24 CN CN202210175449.6A patent/CN114432329A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 唐富山等: "高效液相色谱法测定银屑片中栀子苷的含量", 《中国药房》 * |
| 林熙然;: "抑制血管生成与银屑病的中西医结合治疗研究" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115192589A (en) * | 2022-07-13 | 2022-10-18 | 滴可安(杭州)生物技术有限公司 | Application of neoisoliquiritin in preparation of psoriasis treatment medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105582028A (en) | Use of antrodia camphorata for treating diseases | |
| CN102764408A (en) | Dealcoholic preparation | |
| TWI513478B (en) | Lopamine hydrochloride (LOPERAMIDE) hydrochloride film preparation | |
| CN114432329A (en) | Application of geniposide in preparation of medicine for treating psoriasis | |
| CN102716184A (en) | Chinese medicinal composition and application thereof | |
| CN101278948B (en) | Biological medical membrane and method of preparing the same | |
| CN111437338A (en) | Application of traditional Chinese medicine composition in treating skin diseases | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| CN100335083C (en) | Pile treating Chinese medicine prepn and its production process | |
| CN114272295A (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN102961409B (en) | Toad skin extract dry powder inhaler | |
| WO2019201315A1 (en) | Composition containing phlorizin and 1-deoxynojirimycin and use thereof | |
| JP5265347B2 (en) | Use of konjac and its extract in formulating pharmaceuticals for the treatment of acute and chronic bronchitis | |
| CN101028338B (en) | Oral-cavity disintegrating tablet for treating cardiovascular disease | |
| CN110025705A (en) | A kind of Chinese medicine composition and its preparation method and application for treating atopic dermatitis | |
| CN108355138A (en) | A kind of application of azone in drug transdermal promotees to ooze | |
| CN113244208B (en) | Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease | |
| CN117562895B (en) | Application of atractylenolide I in preparation of medicine for treating allergic purpura | |
| CN112773786B (en) | Application of icariin in preparation of psoriasis treatment medicine | |
| CN1533795A (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN108721274B (en) | Application of arctigenin in preparation of medicine for treating chronic atrophic gastritis | |
| CN102247421B (en) | Chinese herbs paste for treating gastrointestinal dysfunction and preparation method thereof | |
| CN102204975A (en) | Medicinal composition for treating acute and chronic enteritis | |
| CN108404082B (en) | Compound traditional Chinese medicine preparation with effects of promoting blood circulation and relieving pain and preparation method thereof | |
| CN102078369B (en) | Application of Chinese patent drug for treating peptic ulcer in preparing alcohol resistance medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220506 |